-

EUROAPI Strengthens its Executive Committee with the Appointment of Ludwig de Mot as Executive Vice President - Chief Transformation Officer

  • Ludwig de Mot will focus on the acceleration of EUROAPI’s transformation, including the finalization and execution of the strategic review initiated in Q4 2023

PARIS--(BUSINESS WIRE)--Regulatory News:

EUROAPI (Paris:EAPI) today announced the appointment of Ludwig de Mot as Executive Vice President (EVP) - Chief Transformation Officer.

Ludwig de Mot’s roadmap will focus on accelerating the company’s transformation, including the completion and execution of the Strategic Review initiated by EUROAPI’s Board of Directors in Q4 2023. This comprehensive review spans the entire spectrum of EUROAPI as an organization, including the assessment of its current product portfolio, cost structure, and balance sheet.

With over 30 years of experience in several industrial groups, Ludwig de Mot has held various senior executive positions in global companies. This includes his role as President and CEO of the German, North American, and later European and Asian operations of Lhoist, the global lime and mineral-based products and solutions producer, between 2006 and 2017. More recently, Ludwig de Mot served as CEO for companies undergoing transformation.

“Ludwig de Mot is a seasoned executive with strong leadership skills and a solid track record in executing transformation programs. He will be instrumental in the transformation of our company, and I look forward to working with him in the best interests of all our stakeholders,” said Viviane Monges, EUROAPI’s CEO and Chair of the Board of Directors.

Biography of Ludwig de Mot
A graduate of KU Leuven University in Belgium, Ludwig de Mot, a Belgian national, worked for SCA Packaging between 1996 and 2006. He then joined Lhoist, the global lime and mineral-based products and solutions producer, where he held several executive positions in Europe, Asia, and North America until 2017. Ludwig de Mot served as Chief Executive Officer for various international companies, including ArcelorMittal Mining in Canada, McBride in the UK, Swissport in Switzerland and, more recently, Tereos in France. Since May 2022, Ludwig de Mot has been the Chair of the Board of ESCO Couplings and Transmissions (Belgium) and is also a member of the Board of Directors of Graymont (Canada) and VPK Packaging Group (Belgium).

About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

Taking action for health by enabling access to essential therapies inspires our 3,450 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn.

Forward-Looking Statements
Certain information contained in this press release is forward looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions including, but not limited to, assumptions concerning the Group’s current and future strategy, financial and non-financial future results and the environment in which the Group operates, as well as events, operations, future services or product development and potential. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Forward looking statements and information do not constitute guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a large number of which are difficult to predict and generally outside the control of the Group, which could cause actual results, performances or achievements, or the results of the sector or other events, to differ materially from those described or suggested by these forward-looking statements. These risks and uncertainties include those that are indicated and detailed in Chapter 3 “Risk factors” of the Universal Registration Document approved by the French Financial Markets Authority (Autorité des marchés financiers, AMF) on April 14, 2023, under number R.23-009 and the Amendment to Universal Registration Document approved by the AMF on April 25, 2023 under number R.23-015. These forward-looking statements are given only as of the date of this press release and the Group expressly declines any obligation or commitment to publish updates or corrections of the forward-looking statements included in this press release in order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-looking statements are based.

Contacts

Media Relations Contact:
Laurence Bollack
Mob.: +33 (0)6 81 86 80 19
mr@euroapi.com

Investor Relations Contact:
Sophie Palliez-Capian
Mob.: +33 (0)6 87 89 33 51
sophie.palliez@euroapi.com

Camille Ricotier
Mob: +33 (0)6 43 29 93 79
camille.ricotier@euroapi.com

EUROAPI

BOURSE:EAPI

Release Versions

Contacts

Media Relations Contact:
Laurence Bollack
Mob.: +33 (0)6 81 86 80 19
mr@euroapi.com

Investor Relations Contact:
Sophie Palliez-Capian
Mob.: +33 (0)6 87 89 33 51
sophie.palliez@euroapi.com

Camille Ricotier
Mob: +33 (0)6 43 29 93 79
camille.ricotier@euroapi.com

More News From EUROAPI

EUROAPI Enhances Its CDMO Capabilities Through a Pivotal Collaboration With SpiroChem, a Leading Contract Research Organization (CRO)

PARIS & BASEL, Switzerland--(BUSINESS WIRE)--Regulatory News: EUROAPI (Paris:EAPI) announced today that it has initiated a pivotal collaboration with SpiroChem, a leading Contract Research Organization (CRO) with best-in-class status in the field of early Chemical Process R&D (route scouting). SpiroChem is headquartered in Basel, Switzerland. SpiroChem and EUROAPI are joining forces to offer their customers a consolidated CRO-CDMO solution, ensuring that industrialization constraints for sm...

EUROAPI Appoints New Executive Committee Members

PARIS--(BUSINESS WIRE)--Regulatory News: EUROAPI (Paris:EAPI) today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innova...

CDMO: EUROAPI Completes Acquisition of Biano

PARIS--(BUSINESS WIRE)--Regulatory News: EUROAPI (Paris:EAPI) today announced the completion of the acquisition of BianoGMP (“Biano”), strengthening its CDMO expertise in the high-growth oligonucleotide market. This acquisition further differentiates EUROAPI’s value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization. “We are delighted to welcome the talented people of Biano,” said Viviane Monges, EUROAPI’s Chie...
Back to Newsroom